Equities research analysts predict that Minerva Neurosciences Inc (NASDAQ:NERV) will report earnings of ($0.37) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences reported earnings of ($0.28) per share during the same quarter last year, which would indicate a negative year over year growth rate of 32.1%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 5th.
According to Zacks, analysts expect that Minerva Neurosciences will report full year earnings of ($1.39) per share for the current fiscal year. For the next financial year, analysts forecast that the company will report earnings of ($1.56) per share. Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Minerva Neurosciences.
Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06.
In related news, COO Joseph H. Reilly sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the sale, the chief operating officer now directly owns 39,177 shares of the company’s stock, valued at approximately $391,770. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William F. Doyle purchased 4,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average cost of $9.88 per share, with a total value of $39,520.00. Following the completion of the purchase, the director now directly owns 4,000 shares in the company, valued at approximately $39,520. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 8,000 shares of company stock valued at $81,520 and have sold 131,717 shares valued at $1,576,610. 9.60% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the stock. Highland Capital Management LP lifted its stake in shares of Minerva Neurosciences by 4.0% during the 1st quarter. Highland Capital Management LP now owns 2,246,876 shares of the biopharmaceutical company’s stock worth $14,043,000 after acquiring an additional 86,332 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Minerva Neurosciences by 11.2% during the 2nd quarter. BlackRock Inc. now owns 2,181,703 shares of the biopharmaceutical company’s stock worth $17,998,000 after acquiring an additional 219,405 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Minerva Neurosciences by 2.8% during the 2nd quarter. Millennium Management LLC now owns 919,471 shares of the biopharmaceutical company’s stock worth $7,586,000 after acquiring an additional 25,092 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Minerva Neurosciences by 40.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 391,041 shares of the biopharmaceutical company’s stock worth $3,226,000 after acquiring an additional 112,461 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Minerva Neurosciences by 18.7% during the 2nd quarter. Northern Trust Corp now owns 358,803 shares of the biopharmaceutical company’s stock worth $2,960,000 after acquiring an additional 56,592 shares during the last quarter. 71.96% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:NERV traded up $0.01 during trading on Wednesday, hitting $11.39. The company had a trading volume of 101 shares, compared to its average volume of 188,240. The firm has a market capitalization of $486.62 million, a price-to-earnings ratio of -10.58 and a beta of 1.60. Minerva Neurosciences has a one year low of $4.80 and a one year high of $12.95.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Further Reading: How is the discount rate different from the Federal Funds rate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.